ClinicalTrials.gg
RecruitingNCT07122687Updated Jul 27, 2026

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of Pemetrexed and Cisplatin in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Innovent Biologics, Inc. — 6 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Innovent Biologics, Inc..

Planned enrollment
6th of 12
170 · median 157
Started
2025
with 1 other
Phase 2
4 of 13
3 open now
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Innovent Biologics, Inc., this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Innovent Biologics, Inc. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Innovent Biologics, Inc., or all of them as a file.
02

Study summary

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

03

Conditions studied

  • Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and Females, age ≥18 years and ≤75 years;
  2. or cytologically confirmed primary non-squamous NSCLC:

    • Stage IB, II, IIIA or IIIB (N2) NSCLC (per AJCC8);
    • No administration of any anti-NSCLC therapy in the pre-operative period;
    • Be able to undergo the radical resection; Pulmonary function capacity capable of tolerating the proposed lung resection according to the surgeon.
  3. Participants without EGFR mutations or ALK translocation;
  4. At least 1 per v1.1;
  5. (ECOG) Performance Status score of 0-1;
  6. Adequate organ function confirmed at screening period.

Exclusion criteria

Exclusion Criteria:

  1. confirmed the presence of small cell lung cancer, neuroendocrine carcinoma, sarcoma, salivary gland tumor, and mesenchymal tumor components, or mixed NSCLC with predominant squamous cell carcinoma features;
  2. Tumor invasion of surrounding important structures, which is symptomatic or medical intervention indicated;
  3. Pancoast tumor;
  4. Malignant tumor nodule in the contralateral lung lobe;
  5. Participants with known or suspected or other distant ;
  6. Participants who received Chinese herbal medicines, proprietary Chinese medicines with anti-tumor indications, or immunomodulatory drugs within 2 weeks prior to the first dose of the study drug;
  7. Participants with a condition requiring systemic treatment with or is receiving any other form of therapy within 7 days prior the first dose of the study drug;
  8. History of any arterial thromboembolic event within 6 months prior to the first dose of the study drug;
  9. History of deep vein thrombosis, pulmonary embolism, or any other serious venous thromboembolism within 3 months prior to the first dose of study drug;
  10. History of pneumonitis requiring corticosteroid therapy, or history of lung diseases or who are suspected to have these diseases by imaging during the screening period;
  11. Active or uncontrolled diseases or conditions;
  12. History of immunodeficiency disease;
  13. Participants with active disease requiring systemic treatment within 2 years prior to the first dose of the study drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    IBI363

    Neoadjuvant Treatment period: 4 cycles of IBI363 plus platinum-based chemotherapy prior to surgery.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: IBI363 · Drug: Carboplatin

  • Active comparator
    Keytruda

    Neoadjuvant Treatment period: 4 cycles of Keytruda plus platinum-based chemotherapy prior to surgery.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Keytruda

Interventions

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response (pCR) rate

    pCR rate is defined as no residual invasive viable tumor in both the primary tumor (lung) and the sampled lymph nodes after neoadjuvant therapy.

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

  2. Safety parameters: the incidence of all adverse events (AEs)

    Time frame: up to 90 days after the last dose

  3. Safety parameters: the incidence of treatment-emergent adverse events (TEAEs)

    Time frame: up to 90 days after the last dose

  4. Safety parameters: the incidence of immune-related adverse events (irAEs)

    Time frame: up to 90 days after the last dose

  5. Safety parameters: the incidence of adverse events of special interest (AESIs)

    Time frame: up to 90 days after the last dose

  6. Safety parameters: the incidence of serious adverse events (SAE)

    Time frame: up to 90 days after the last dose

  7. Safety parameters: the relatedness of infusion-related reactions (IRRs) to the investigational product and their severity

    Time frame: up to 90 days after the last dose

  8. Safety parameters: the surgery delay rate

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

  9. Proportion of subjects with abnormal and clinically significant results including routine blood tests, blood biochemical tests, coagulation tests,, routine urine tests, pregnancy tests,ECG, etc

    Time frame: up to 90 days after the last dose

Secondary outcomes

  1. Event Free Survival (EFS)

    EFS is defined as the time from the first dose to the first determination by the investigator with RECIST v1.1 of inoperable disease progression, postoperative local recurrence or distant metastasis, development of another primary tumor, or death from any cause, whichever occurred first.

    Time frame: Up to approximately 5 years

  2. Major Pathological Response (mPR) Rate

    mPR rate is defined as ≤ 10% residual invasive viable tumor in both the primary tumor (lung) and the sampled lymph nodes after neoadjuvant therapy.

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

  3. Objective Response Rate (ORR)Rate

    ORR is defined as the proportion of subjects assessed by the investigators as achieving complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria.

    Time frame: Up to approximately 5 years

  4. Disease Control Rate (DCR) Rate

    ORR is defined as the proportion of subjects assessed by the investigators as achieving complete response (CR) 、partial response (PR) or stable Disease(SD) according to the RECIST v1.1 criteria.

    Time frame: Up to approximately 5 years

  5. R0 resection rate

    R0 resection rate is defined as negative margins, systematic lymph node dissection or sampling, and tumor-negative highest mediastinal lymph nodes.

    Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment

07

Study locations

1 of 1 sites recruiting
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110000, China
    Recruiting
    • Hongxu Liu · Contacthongxuliu@qq.com · 024-81916272
    • Jianxing He · Principal investigator
    • Hongxu Liu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2026, 15 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 15 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Aug 14, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Apr 30, 2030
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07122687
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 26, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Jul 27, 2026

Study contacts

xiao zhang
Contact
kobe.zhang@innoventbio.com
17631117415

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion